BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 20669280)

  • 1. Effects of long-term etanercept treatment on growth in children with selected categories of juvenile idiopathic arthritis.
    Giannini EH; Ilowite NT; Lovell DJ; Wallace CA; Rabinovich CE; Reiff A; Higgins G; Gottlieb B; Chon Y; Zhang N; Baumgartner SW
    Arthritis Rheum; 2010 Nov; 62(11):3259-64. PubMed ID: 20669280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry.
    Horneff G; De Bock F; Foeldvari I; Girschick HJ; Michels H; Moebius D; Schmeling H;
    Ann Rheum Dis; 2009 Apr; 68(4):519-25. PubMed ID: 18413440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register.
    Prince FH; Twilt M; ten Cate R; van Rossum MA; Armbrust W; Hoppenreijs EP; van Santen-Hoeufft M; Koopman-Keemink Y; Wulffraat NM; van Suijlekom-Smit LW
    Ann Rheum Dis; 2009 May; 68(5):635-41. PubMed ID: 18413443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of measles, mumps and rubella revaccination in children with juvenile idiopathic arthritis treated with methotrexate and etanercept.
    Borte S; Liebert UG; Borte M; Sack U
    Rheumatology (Oxford); 2009 Feb; 48(2):144-8. PubMed ID: 19074187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The German etanercept registry for treatment of juvenile idiopathic arthritis.
    Horneff G; Schmeling H; Biedermann T; Foeldvari I; Ganser G; Girschick HJ; Hospach T; Huppertz HI; Keitzer R; Küster RM; Michels H; Moebius D; Rogalski B; Thon A;
    Ann Rheum Dis; 2004 Dec; 63(12):1638-44. PubMed ID: 15115709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Etanercept improves linear growth and bone mass acquisition in MTX-resistant polyarticular-course juvenile idiopathic arthritis.
    Billiau AD; Loop M; Le PQ; Berthet F; Philippet P; Kasran A; Wouters CH
    Rheumatology (Oxford); 2010 Aug; 49(8):1550-8. PubMed ID: 20444859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Etanercept treatment improves longitudinal growth in prepubertal children with juvenile idiopathic arthritis.
    Vojvodich PF; Hansen JB; Andersson U; Sävendahl L; Hagelberg S
    J Rheumatol; 2007 Dec; 34(12):2481-5. PubMed ID: 18050366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of inflammatory bowel disease in patients with juvenile idiopathic arthritis treated with etanercept.
    van Dijken TD; Vastert SJ; Gerloni VM; Pontikaki I; Linnemann K; Girschick H; Armbrust W; Minden K; Prince FH; Kokke FT; Nieuwenhuis EE; Horneff G; Wulffraat NM
    J Rheumatol; 2011 Jul; 38(7):1441-6. PubMed ID: 21459936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients.
    Gerloni V; Pontikaki I; Gattinara M; Fantini F
    Ann Rheum Dis; 2008 Aug; 67(8):1145-52. PubMed ID: 17981916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug survival of the first and second course of anti-tumour necrosis factor agents in juvenile idiopathic arthritis.
    Tynjälä P; Vähäsalo P; Honkanen V; Lahdenne P
    Ann Rheum Dis; 2009 Apr; 68(4):552-7. PubMed ID: 18467515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type.
    Quartier P; Taupin P; Bourdeaut F; Lemelle I; Pillet P; Bost M; Sibilia J; Koné-Paut I; Gandon-Laloum S; LeBideau M; Bader-Meunier B; Mouy R; Debré M; Landais P; Prieur AM
    Arthritis Rheum; 2003 Apr; 48(4):1093-101. PubMed ID: 12687553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of response criteria to evaluate therapeutic response in patients with juvenile idiopathic arthritis treated with methotrexate and/or anti-tumor necrosis factor alpha agents.
    Lurati A; Pontikaki I; Teruzzi B; Desiati F; Gerloni V; Gattinara M; Cimaz R; Fantini F
    Arthritis Rheum; 2006 May; 54(5):1602-7. PubMed ID: 16646003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of etanercept in a cohort of patients with juvenile idiopathic arthritis under 4 years of age.
    Bracaglia C; Buonuomo PS; Tozzi AE; Pardeo M; Nicolai R; Campana A; Insalaco A; Cortis E; DE Benedetti F
    J Rheumatol; 2012 Jun; 39(6):1287-90. PubMed ID: 22589254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum osteopontin as a predictive marker of responsiveness to methotrexate in juvenile idiopathic arthritis.
    Masi L; Ricci L; Zulian F; Del Monte F; Simonini G; Capannini S; De Martino M; Brandi ML; Falcini F
    J Rheumatol; 2009 Oct; 36(10):2308-13. PubMed ID: 19684155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advanced therapy for juvenile arthritis.
    Murray KJ; Lovell DJ
    Best Pract Res Clin Rheumatol; 2002 Jul; 16(3):361-78. PubMed ID: 12387805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complete control of disease activity and remission induced by treatment with etanercept in juvenile idiopathic arthritis.
    Papsdorf V; Horneff G
    Rheumatology (Oxford); 2011 Jan; 50(1):214-21. PubMed ID: 21148155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group.
    Lovell DJ; Giannini EH; Reiff A; Cawkwell GD; Silverman ED; Nocton JJ; Stein LD; Gedalia A; Ilowite NT; Wallace CA; Whitmore J; Finck BK
    N Engl J Med; 2000 Mar; 342(11):763-9. PubMed ID: 10717011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of once weekly etanercept 0.8 mg/kg in a multicentre 12 week trial in active polyarticular course juvenile idiopathic arthritis.
    Horneff G; Ebert A; Fitter S; Minden K; Foeldvari I; Kümmerle-Deschner J; Thon A; Girschick HJ; Weller F; Huppertz HI
    Rheumatology (Oxford); 2009 Aug; 48(8):916-9. PubMed ID: 19483091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. When and how to stop etanercept after successful treatment of patients with juvenile idiopathic arthritis.
    Prince FH; Twilt M; Simon SC; van Rossum MA; Armbrust W; Hoppenreijs EP; Kamphuis S; van Santen-Hoeufft M; Koopman-Keemink Y; Wulffraat NM; ten Cate R; van Suijlekom-Smit LW
    Ann Rheum Dis; 2009 Jul; 68(7):1228-9. PubMed ID: 19525408
    [No Abstract]   [Full Text] [Related]  

  • 20. The safety and efficacy of adding etanercept to methotrexate or methotrexate to etanercept in moderately active rheumatoid arthritis patients previously treated with monotherapy.
    van der Heijde D; Burmester G; Melo-Gomes J; Codreanu C; Mola EM; Pedersen R; Freundlich B; Chang DJ;
    Ann Rheum Dis; 2008 Feb; 67(2):182-8. PubMed ID: 17728331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.